Compare TG & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TG | SBFM |
|---|---|---|
| Founded | 1988 | 2006 |
| Country | United States | United States |
| Employees | N/A | 50 |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 353.3M | 4.9M |
| IPO Year | 1994 | N/A |
| Metric | TG | SBFM |
|---|---|---|
| Price | $7.96 | $0.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 184.8K | ★ 9.3M |
| Earning Date | 05-08-2026 | 04-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 151.06 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $800,821,000.00 | N/A |
| Revenue This Year | N/A | $40.47 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $44.88 | ★ N/A |
| Revenue Growth | ★ 8.29 | N/A |
| 52 Week Low | $6.25 | $0.28 |
| 52 Week High | $10.53 | $2.43 |
| Indicator | TG | SBFM |
|---|---|---|
| Relative Strength Index (RSI) | 40.85 | 37.79 |
| Support Level | $7.30 | N/A |
| Resistance Level | $8.04 | $1.45 |
| Average True Range (ATR) | 0.58 | 0.22 |
| MACD | -0.24 | -0.05 |
| Stochastic Oscillator | 25.07 | 12.48 |
Tredegar Corp is engaged in the manufacture of aluminum extrusions and polyethylene and polypropylene plastic films. It produces surface protection films, packaging films and films for other markets. The company continues to have two reportable segments: Aluminum Extrusions and High Performance Films. The majority of the revenue is derived form the Aluminum Extrusions segment which produces high-quality, soft and medium strength alloyed aluminum extrusions, custom fabricated and finished, for the building and construction, automotive and transportation, consumer durables goods, machinery and equipment, electrical and renewable energy, and distribution markets.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.